Leukemization of follicular lymphoma: The features of diagnostic and clinical course of a rare form of the disease


Cite item

Full Text

Abstract

Aim. To characterize a group of patients with follicular lymphoma (FL) with leukemization and to evaluate the efficiency of different therapy options (R-CHOP/R-FMC/high-dose chemotherapy (HDCT)). Subjects and methods. 18 (7.2%) out of 250 patients diagnosed with FL, who were examined and treated at the National Research Center for Hematology, Ministry of Health of the Russian Federation, were found to have leukemic FL (tumor cells in the peripheral blood smears were detected by cytology and flow cytofluorometry. Eight of the 18 patients had extranodal foci of involvement: lung, stomach, spleen, lumbar muscles, upper jaw, and vertebrae. Bone marrow was involved in 17 of the 18 patients. Tumor biopsy specimens displayed a morphological pattern of indolent FL in the majority of patients (10 of the 18 patients had cytological grade 1—2 tumors and 14 patients had a nodular or nodular-diffuse tumor growth pattern). The patients underwent R-CHOP/R-FMC) or HDCT cycles as first-line therapy, followed by autologous stem cell transplantation (auto-SCT). Results. The median follow-up was 66 months (range 12—217 months). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 70% (10% SEM) and 35% (15% SEM), respectively. The median OS was not reached; the median PFS was 3 years. Conclusion. Leukemic FL is characterized by low OS and PFS rates. The most effective chemotherapy regimens were R-CHOP, followed by HDCT and auto-SCT in first remission or R-FMC. These cycles can to a greater extent achieve a complete eradication of the bone marrow tumor clone. Due to the relapsing course of FL and the aggressiveness of leukemic FL, it is expedient to carry out auto-SCT in first remission.

About the authors

E S Nesterova

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

S K Kravchenko

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

Ya K Mangasarova

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

L V Plastinina

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

V N Dvirnyk

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

A M Kovrigina

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

I A Shchupletsova

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

T N Obukhova

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

E G Gemdzhian

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

I A Vorobyev

ФГОУ ВО «МГУ им. М.В. Ломоносова», Москва, Россия

A I Vorobyev

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

References

  1. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D,Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004-4013.
  2. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C,Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P,Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
  3. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M,Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555-4562.
  4. Лорие Ю.И., Соловьева Е.А., Круглова Г.В. Клинико-морфологические параллели при лейкемизации лимфосаркомы по пролимфоцитарному типу. Проблемы гематологии. 1975;10:3-8.
  5. Chim CS, Loong F, Leung AY. et al. Primary follicular lymphoma of the small intestine. Leuk Lymphoma. 2004;45(7):1463-1466.
  6. Fernandez de Larrea C, Martinez-Pozo A, Mercadal S, et al. Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol. 2011; 153(3):334-340.
  7. Goodlad JR, MacPherson S, Jackson R. et al. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology. 2004;44(3):268-276.
  8. Martinelli G, Ryan G, Seymour JF. et al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2009;20(12):1993-1999.
  9. Anday GJ, Schmitz HL. Follicular lymphoma with transient leukemic phase; brief review of literature and report of a case. AMA Arch Intern Med. 1952;89(4):621-634.
  10. Brady E. Beltran, Jorge J. Castillo, Pilar Quiсones3, Domingo Morales, Jose C. Alva, Roberto N. Miranda, Bijal D. Shah5, and Eduardo M. Sotomayor. Follicular lymphoma with leukemic phase at diagnosis: An aggressive disease. Report of seven cases and review of the literature. Leuk Res. 2013;37(9):1116-1119. https://doi.org/10.1016/j.leukres.2013.05.016
  11. Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Muller-Hermelink HK, Ullrich FA, Weisenburger DD. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin’s Lymphoma Classification Project. Hum Pathol. 1999;30(3):263-268.
  12. Al-Nawakil C, Kosmider O, Stern MH, Manié E, Bardet V, Leblond V, Park S, Dreyfus F, Bouscary D, Tamburini J. Leukemic phase of follicular lymphomas: an atypical presentation. Leuk Lymphoma. 2011;52(8):1504-1508.
  13. Rymkiewicz G, Paszkiewicz-Kozik E, Blachnio K, Pastwiska A, Kulik J, Pienkowska-Grela B, Walewski J. Unusual IgD+/CD38-follicular lymphoma with leukemic presentation. Med Oncol. 2006;23(1):131-135.
  14. Ono Y, Aoki K, Kato A, Arima H, Takiuchi Y, Nagano S, Tabata S, Yanagita S, Matsushita A, Maruoka H, Imai Y, Ishikawa T, Takahashi T. Systemic follicular lymphoma with massive intestinal involvement with leukemic manifestation. J Clin Exp Hematop. 2011;51(2):135-140.
  15. Kodaira M, Takeuchi K, Nara E. Leukemic Presentation Is Predictive Indicator for Relapse for Patients with Follicular Lymphoma Treated with Rituximab Containing Initial Therapy. ASH Annual Meeting Abstracts. 2009;114(22):4763.
  16. Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M,Lopez-Guillermo A, Berger F, Coiffier B, Felman P, Salles G. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. BrJHaematol. 2014;164(5):659-667. https://doi.org/ 10.1111/bjh.12675
  17. Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). Leuk. Lymphoma. 2011;52(3):409-416.
  18. Charles J. Dimitroff, Jack Y. Lee, Robert C. Fuhlbrigge, Robert Sackstein. A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci USA. 2000;97(25):13841-13846. https://doi.org/10.1073/pnas.250484797
  19. Hiddemann W, Kneba M, Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732.
  20. Marcus R, Imrie K, Solal-Celigny P. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
  21. Frédéric Mourcin, Céline Pangault, Rada Amin-Ali, Patricia Amé-Thomas, Karin Tarte. Stromal Cell Contribution to Human Follicular Lymphoma Pathogenesis. Front Immunol. 2012;3:280. https://doi.org/10.3389/fimmu.2012.00280
  22. Charles J. Dimitroff, Jack Y. Lee, Robert C. Fuhlbrigge, Robert Sackstein. A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci USA. 2000; 97(25):13841-13846. https://doi.org/10.1073/pnas.250484797
  23. Niitsu N, Iijima K. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Leuk Res. 2002;26(3):241-248.
  24. Sarah L. Ondrejka and Eric D. His. Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery. Springer International Publishing Switzerland 2015 A.M. Evens and K.A. Blum (eds.), Non-Hodgkin Lymphoma, Cancer Treatment and Research 165, DOI 10.
  25. Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S, Delarue R, Pedersen LM, Mounier C, Gomes Da Silva M, Chassagne-Clement C, Maerevoet M, Salles G. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood. 2014;123(17):2740-2742. https://doi.org/10.1182/blood-2014-02-553693
  26. Nina Shah, Fernando Cabanillas, Bradley McIntyre, Lei Feng, Peter McLaughlin, Maria A. Rodriguez, Jorge Romaguera, Anas Younes, Fredrick B. Hagemeister, Larry Kwak, and Luis Fayad. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin lymphomas. Blood. 2014; 123(17):2740-2742. https://doi.org/10.1182/blood-2014-02-553693
  27. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S, Ponta H. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci. 2000;910:106-118.discussion 118-120.
  28. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med. 1994;180:53-66.
  29. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754-4756.
  30. Holland J, Owens T. Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway. J Biol Chem. 1997;272:9108-9112.
  31. Deem TL, Abdala-Valencia H, Cook-Mills JM. VCAM-1 activation of endothelial cell protein tyrosine phosphatase 1B. J Immunol. 2007;178:3865-3873.
  32. Нестерова Е.С., Кравченко С.К., Гемджян Э.Г., Магомедова А.У., Капланская И.Б., Ковригина А.М., Барях Е.А., Кременецкая А.М. Итоги десятилетнего опыта лечения больных фолликулярной лимфомой. Гематология и трансфузиология. 2012;5:3-8.
  33. Нестерова Е.С., Кравченко С.К., Гемджян Э.Г., Османов Е.А., Ковригина А.М. Оценка васкуляризации и микроокружения опухолевой ткани при фолликулярной лимфоме. Терапевтический архив. 2013;85(7):57-64.
  34. Нестерова Е.С., Ковригина А.М., Гемджян Э.Г., Магомедова А.У., Барях Е.А., Чернова Н.Г., Марьин Д.С., Гаврилина О.А., Лукина А.Е., Васильева К.С., Кравченко С.К. Опыт применения высокодозной терапии с последующей ауто-ТСКК при фолликулярной лимфоме в первой линии терапии. Гематология и трансфузиология. 2014;59(S1):54-55.
  35. Nesterova ES, Kravchenko SK, Kovrigina AM, Gemdzhian EG, Magomedova AU, Bariakh EA, Vorobyev VI, Iliushkina EA, Mariin DS, Chernova NG, Gavrilina OA, Lukina AE, Savchenko VG. Front-Line High Dose Therapy with Following Autologous Stem Cell Transplantation (ASCT) for Follicular Lymphoma Patients. Blood. 2014;124:5908.
  36. Nesterova ES, Kravchenko SK, Gemdjian EG, Kovrigina AM, Osmanov EA. Tumor associated cytotoxic lymphocytes and macrophages as predictive factors in follicular lymphoma. Biochemistry (Moscow) Supplement. Series A: Membrane and Cell Biology. 2014;(2):198-205.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies